Innovating Works

ST. ANNA KINDERKREBSFORSCHUNG

Desconocido
Showing 1 to 20 of 23 results
PanCareSurPass: PanCare studies of the scale up and implementation of the digital Survivorship Passport to improve p... ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-SC1-BHC-2018-2020 Almost 500,000 former childhood cancer patients (CCS) are now living in Europe. Compared to the general population, CCS represent a vulnerab...
2021-01-21 - 2025-02-28 | Financiado
ERICA: European Rare dIsease research Coordination and support Action ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-SC1-BHC-2018-2020 Rare diseases are defined as diseases that affect not more than 1 person per 2000 in the European population. While individual rare diseases...
2021-01-15 - 2025-02-28 | Financiado
FIND-seq: Functional Interrogation of Non coding DNA Sequences in leukemia development and drug resistance ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: ERC-2020-STG Functional non-coding regions of the genome play a fundamental role in gene expression and are enriched for disease associated variants. Per...
2020-11-09 - 2026-02-28 | Financiado
VAGABOND: Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate students ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-MSCA-ITN-2020 Pre-clinical drug development for paediatric cancers is very complex, resource intensive and requiring multi-disciplinary expertise and inno...
2020-08-18 - 2024-11-30 | Financiado
TREL: Twinning in Research and Education to improve survival in Childhood Solid Tumours in Lithuania ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-WIDESPREAD-2018-2020 Vilnius University Hospital Santaros Klinikos (VULSK) acts as a coordinator of the TREL (Twinning in Research and Education to improve survi...
2020-06-12 - 2023-12-31 | Financiado
Instand-NGS4P: Integrated and standardized NGS workflows for Personalised therapy ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-SC1-BHC-2018-2020 Instand-NGS4P is a 65-month PCP project federating 7 leading medical centers (two are coordinating ERNs) as buyers’ group with major experie...
2019-12-13 - 2025-05-31 | Financiado
iDysChart: Charting key molecules and mechanisms of human immune Dysregulation ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: ERC-2018-COG The central challenge for the immune system is to efficiently recognize and neutralize foreign antigen while protecting self. If the latter...
2019-03-20 - 2025-05-31 | Financiado
EJP RD: European Joint Programme on Rare Diseases ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-SC1-BHC-2018-2020 As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profi...
2018-12-13 - 2024-08-31 | Financiado
CLOSER: Childhood Leukemia Overcoming distance between South America and Europe Regions ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-SC1-BHC-2018-2020 Cancer has become an important public health problem worldwide and inequalities in access to malignancies control result in differences in p...
2018-12-10 - 2024-03-31 | Financiado
PRIMAGE: PRedictive In silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis Em... ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-SC1-DTH-2018-2020 PRIMAGE proposes a cloud-based platform to support decision making in the clinical management of malignant solid tumours, offering predictiv...
2018-11-14 - 2023-05-31 | Financiado
ITCC-P4: ITCC Pediatric Preclinical POC Platform Sofia ref. 116064 ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant s...
2017-05-18 - 2023-12-31 | Financiado
ChiLTERN: Children s Liver Tumour European Research Network ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un H2020: H2020-PHC-2014-2015 Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in...
2015-12-07 - 2021-12-31 | Financiado
DIRECT: DIsseminate Research funded by EC improving Treatment options for children suffering from cancer ST ANNA KINDERKREBSFORSCHUNG VEREIN tramitó un FP7: Science is an endeavour that relies on a society committed to allocate substantial resources to its pursuit. Clear communication of research...
Financiado
FUNGITECT: Optimized Diagnostics for Improved Treatment Stratification in Invasive Fungal Diseases ST ANNA KINDERKREBSFORSCHUNG VEREIN tramitó un FP7: Invasive fungal disease (IFD) is a leading cause of morbidity and mortality in the growing number of immunocompromised individuals, includin...
Financiado
ENCCA: EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS ST ANNA KINDERKREBSFORSCHUNG VEREIN tramitó un FP7: ENCCA aims to establish a durable, European Virtual Institute clinical and translational research in childhood and adolescent cancers that w...
Financiado
MODICELL: Targeted Modulation of Immune System Responses in Cell Therapies ST ANNA KINDERKREBSFORSCHUNG VEREIN tramitó un FP7: Cell-based immunotherapies are a modern treatment approach holding promise to utilize nature’s own power to treat diseases that develop on t...
Financiado
ASSET: ASSET Analysing and Striking the Sensitivities of Embryonal Tumours ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un FP7: Cancer is hallmarked by multiple genetic aberrations that lead to a functional derangement of cellular signalling networks. Embryonal tumour...
Financiado
EEC: EURO EWING Consortium International Clinical Trials to Improve Survival from Ewing Sarcoma ST ANNA KINDERKREBSFORSCHUNG VEREIN participó en un FP7: Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.